Treatment of lung cancer by radiotherapy, chemotherapy, and methanol extraction residue of BCG (MER). Clinical and immunological studies
โ Scribed by Eliezer Robinson; Arieh Bartal; Yoram Cohen; Robert Haasz; Tamar Mekori
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- English
- Weight
- 455 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
One-hundred-three patients with extensive non-small-cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and A
Effects of the addition of MER, a nonspecific, nonviable immunostimulant, to two combination chemotherapy programs were explored in patients with metastatic breast cancer. Patients were randomized to either CDVFP [cyclophosphamide (C), doxorubicin (D), vincristine (V), fluorouracil (F) and prednison
Background. Induction chemotherapy with cisplatin and fluorouracil and radiotherapy is an effective alternative to surgery in patients with carcinoma of the larynx and hypopharynx who are treated for organ preservation. Methods. We designed a protocol to evaluate the possibility of organ preservati